Circulating tumor cells in hepatocellular carcinoma

肝细胞癌中的循环肿瘤细胞

• 批准号: 8425656
• 负责人: Rahmi Oklu
• 金额: $ 8.7万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-01 至 2015-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8425656
• 关键词: Achievement; Aftercare; Antibodies; Biological Assay; Biological Markers; Biopsy; Biopsy Specimen; Blood; Blood donor; Cell Separation; Cells; Clinical; Clinical Medicine; Data; Detection; Devices; Diagnosis; Disease; Early Diagnosis; Early treatment; Enrollment; Europe; Evaluation; Excision; Future; Goals; Gold; Hepatic Mass; Image; Laboratories; Liver; Magnetic Resonance Imaging; Malignant Epithelial Cell; Malignant Neoplasms; Malignant neoplasm of liver; Medical; Medicine; Microfluidics; Monitor; Neoplasm Circulating Cells; Operative Surgical Procedures; Organ; Pathologist; Patients; Pilot Projects; Primary Neoplasm; Primary carcinoma of the liver cells; Radiation; Randomized Clinical Trials; Recurrence; Reproducibility; Research; Resected; Risk; Sensitivity and Specificity; Staging; Surface; Survival Rate; Technology; Testing; Tissues; Transplantation; Tumor Burden; Ultrasonography; Venous; Whole Blood; alpha-Fetoproteins; base; cohort; cost effective; diagnostic accuracy; improved; liver transplantation; neoplastic cell; public health relevance; screening; tool

DESCRIPTION (provided by applicant): We propose to use an antibody-coated microfluidic surface-capture device, the Herringbone CTC-chip, to isolate hepatocellular carcinoma (HCC) circulating tumor cells (CTCs) from venous blood. Successful isolation of these cells from the venous blood of HCC patients has the potential to substantially improve current medical practice by enabling early detection and monitoring of therapy in HCC patients. Survival from HCC is entirely dependent on early detection whether its detection of the primary tumor or recurrence after treatment. Screening, early diagnosis and detection of recurrence have been formidable challenges and despite massive worldwide research efforts, the five-year survival rate of HCC patients remains to be poor. We propose to develop and optimize the CTC-chip for HCC CTC isolation (Aim 1). We will then determine the diagnostic accuracy of the CTC analysis compared to biopsy evaluation of unknown liver masses (Aim 2). The critical value of Aim 2 is to determine the sensitivity and the specificity of the technology to detect HCC CTCs in patients with cancer (n=40) and without cancer (n=40).

描述（由申请人提供）：我们建议使用抗体涂层的微流体表面捕获装置，人字形CTC-CHIP，以分离肝细胞癌（HCC）循环肿瘤细胞（CTC）与静脉血液中。这些细胞从HCC患者的静脉血液中成功隔离，有可能通过早期检测和监测HCC患者的治疗，从而大大改善当前的医疗实践。 HCC的存活完全取决于早期检测是对原发性肿瘤或治疗后复发的检测。筛查，早期诊断和对复发性的检测是巨大的挑战，尽管全球研究工作进行了巨大的研究，但HCC患者的五年生存率仍然很差。我们建议开发和优化用于HCC CTC隔离的CTC-CHIP（AIM 1）。然后，我们将确定CTC分析的诊断准确性与对肝脏肿块的活检评估相比（AIM 2）。 AIM 2的临界值是确定检测癌症患者HCC CTC（n = 40）且无癌症（n = 40）的技术的敏感性和特异性。